Global Metabolic Disease Treatment Market

Metabolic Disease Treatment Comprehensive Study by Type (Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug, Amino Acid Metabolism Drug), Application (Hospital, Retail Pharmacy), Route of Administration (Inhalation, Injection, Other) Players and Region - Global Market Outlook to 2030

Metabolic Disease Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Metabolic Disease Treatment
Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc. A metabolic disorder occurs when abnormal chemical reactions in the body disrupt the body process. Increasing incidences of Inherited metabolic diseases due to changing lifestyles and rising number of diabetic patients boosting the metabolic disease treatment market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global metabolic disease treatment market is fragmented with numerous market players. Due to the rising drug approvals, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Metabolic Disease Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck & Co., Inc (United States), Novartis International AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca plc (United Kingdom), C.H. Boehringer Sohn AG & Ko. KG (Germany) and Kowa Pharmaceuticals America, Inc (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are LG Life Science (South Korea), Mitsubishi Tanabe Pharma Corporation (Japan) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Metabolic Disease Treatment market by Type (Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug and Amino Acid Metabolism Drug), Application (Hospital and Retail Pharmacy) and Region.



On the basis of geography, the market of Metabolic Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Inhalation will boost the Metabolic Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements in Drug Delivery Technologies

Market Growth Drivers:
Increasing incidences of Inherited Metabolic Diseases due to Changing Lifestyles and Rising Number of Diabetic Patients

Challenges:
Side Effects of the Drugs

Restraints:
Straight Government Regulation Related to Drug Production

Opportunities:
High Healthcare Expenditure and Raising Awareness about Metabolic Disease in Developing Countries and Growing Healthcare Infrastructure in the Developing Economies

Market Leaders and their expansionary development strategies
In August 2023, Novo Nordisk A/S and Inversago Pharma announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
In December 2023, The FDA is creating a new advisory committee made up of nine voting members who will provide insight into potential treatments for genetic metabolic diseases.


Key Target Audience
Metabolic Disease Treatment Drugs Manufacturers, Metabolic Disorders Drugs Suppliers, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Potential Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Glycogen Metabolism Disease Drug
  • Lipid Metabolism Disease Drug
  • Amino Acid Metabolism Drug
By Application
  • Hospital
  • Retail Pharmacy
By Route of Administration
  • Inhalation
  • Injection
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing incidences of Inherited Metabolic Diseases due to Changing Lifestyles
      • 3.2.2. Rising Number of Diabetic Patients
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of the Drugs
    • 3.4. Market Trends
      • 3.4.1. Advancements in Drug Delivery Technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Metabolic Disease Treatment, by Type, Application, Route of Administration and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Metabolic Disease Treatment (Value)
      • 5.2.1. Global Metabolic Disease Treatment by: Type (Value)
        • 5.2.1.1. Glycogen Metabolism Disease Drug
        • 5.2.1.2. Lipid Metabolism Disease Drug
        • 5.2.1.3. Amino Acid Metabolism Drug
      • 5.2.2. Global Metabolic Disease Treatment by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Retail Pharmacy
      • 5.2.3. Global Metabolic Disease Treatment by: Route of Administration (Value)
        • 5.2.3.1. Inhalation
        • 5.2.3.2. Injection
        • 5.2.3.3. Other
      • 5.2.4. Global Metabolic Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Metabolic Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. C.H. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kowa Pharmaceuticals America, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Metabolic Disease Treatment Sale, by Type, Application, Route of Administration and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Metabolic Disease Treatment (Value)
      • 7.2.1. Global Metabolic Disease Treatment by: Type (Value)
        • 7.2.1.1. Glycogen Metabolism Disease Drug
        • 7.2.1.2. Lipid Metabolism Disease Drug
        • 7.2.1.3. Amino Acid Metabolism Drug
      • 7.2.2. Global Metabolic Disease Treatment by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Retail Pharmacy
      • 7.2.3. Global Metabolic Disease Treatment by: Route of Administration (Value)
        • 7.2.3.1. Inhalation
        • 7.2.3.2. Injection
        • 7.2.3.3. Other
      • 7.2.4. Global Metabolic Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Metabolic Disease Treatment: by Type(USD Million)
  • Table 2. Metabolic Disease Treatment Glycogen Metabolism Disease Drug , by Region USD Million (2018-2023)
  • Table 3. Metabolic Disease Treatment Lipid Metabolism Disease Drug , by Region USD Million (2018-2023)
  • Table 4. Metabolic Disease Treatment Amino Acid Metabolism Drug , by Region USD Million (2018-2023)
  • Table 5. Metabolic Disease Treatment: by Application(USD Million)
  • Table 6. Metabolic Disease Treatment Hospital , by Region USD Million (2018-2023)
  • Table 7. Metabolic Disease Treatment Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 8. Metabolic Disease Treatment: by Route of Administration(USD Million)
  • Table 9. Metabolic Disease Treatment Inhalation , by Region USD Million (2018-2023)
  • Table 10. Metabolic Disease Treatment Injection , by Region USD Million (2018-2023)
  • Table 11. Metabolic Disease Treatment Other , by Region USD Million (2018-2023)
  • Table 12. South America Metabolic Disease Treatment, by Country USD Million (2018-2023)
  • Table 13. South America Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 14. South America Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 15. South America Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 16. Brazil Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 17. Brazil Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 18. Brazil Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 19. Argentina Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 20. Argentina Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 21. Argentina Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 22. Rest of South America Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 23. Rest of South America Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 24. Rest of South America Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 25. Asia Pacific Metabolic Disease Treatment, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 27. Asia Pacific Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 28. Asia Pacific Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 29. China Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 30. China Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 31. China Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 32. Japan Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 33. Japan Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 34. Japan Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 35. India Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 36. India Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 37. India Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 38. South Korea Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 39. South Korea Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 40. South Korea Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 41. Taiwan Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 42. Taiwan Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 43. Taiwan Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 44. Australia Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 45. Australia Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 46. Australia Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 50. Europe Metabolic Disease Treatment, by Country USD Million (2018-2023)
  • Table 51. Europe Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 52. Europe Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 53. Europe Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 54. Germany Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 55. Germany Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 56. Germany Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 57. France Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 58. France Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 59. France Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 60. Italy Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 61. Italy Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 62. Italy Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 63. United Kingdom Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 64. United Kingdom Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 65. United Kingdom Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 66. Netherlands Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 67. Netherlands Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 68. Netherlands Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 69. Rest of Europe Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 70. Rest of Europe Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 71. Rest of Europe Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 72. MEA Metabolic Disease Treatment, by Country USD Million (2018-2023)
  • Table 73. MEA Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 74. MEA Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 75. MEA Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 76. Middle East Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 77. Middle East Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 78. Middle East Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 79. Africa Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 80. Africa Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 81. Africa Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 82. North America Metabolic Disease Treatment, by Country USD Million (2018-2023)
  • Table 83. North America Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 84. North America Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 85. North America Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 86. United States Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 87. United States Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 88. United States Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 89. Canada Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 90. Canada Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 91. Canada Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 92. Mexico Metabolic Disease Treatment, by Type USD Million (2018-2023)
  • Table 93. Mexico Metabolic Disease Treatment, by Application USD Million (2018-2023)
  • Table 94. Mexico Metabolic Disease Treatment, by Route of Administration USD Million (2018-2023)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Metabolic Disease Treatment: by Type(USD Million)
  • Table 102. Metabolic Disease Treatment Glycogen Metabolism Disease Drug , by Region USD Million (2025-2030)
  • Table 103. Metabolic Disease Treatment Lipid Metabolism Disease Drug , by Region USD Million (2025-2030)
  • Table 104. Metabolic Disease Treatment Amino Acid Metabolism Drug , by Region USD Million (2025-2030)
  • Table 105. Metabolic Disease Treatment: by Application(USD Million)
  • Table 106. Metabolic Disease Treatment Hospital , by Region USD Million (2025-2030)
  • Table 107. Metabolic Disease Treatment Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 108. Metabolic Disease Treatment: by Route of Administration(USD Million)
  • Table 109. Metabolic Disease Treatment Inhalation , by Region USD Million (2025-2030)
  • Table 110. Metabolic Disease Treatment Injection , by Region USD Million (2025-2030)
  • Table 111. Metabolic Disease Treatment Other , by Region USD Million (2025-2030)
  • Table 112. South America Metabolic Disease Treatment, by Country USD Million (2025-2030)
  • Table 113. South America Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 114. South America Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 115. South America Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 116. Brazil Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 117. Brazil Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 118. Brazil Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 119. Argentina Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 120. Argentina Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 121. Argentina Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 122. Rest of South America Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 123. Rest of South America Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 124. Rest of South America Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 125. Asia Pacific Metabolic Disease Treatment, by Country USD Million (2025-2030)
  • Table 126. Asia Pacific Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 127. Asia Pacific Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 128. Asia Pacific Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 129. China Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 130. China Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 131. China Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 132. Japan Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 133. Japan Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 134. Japan Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 135. India Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 136. India Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 137. India Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 138. South Korea Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 139. South Korea Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 140. South Korea Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 141. Taiwan Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 142. Taiwan Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 143. Taiwan Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 144. Australia Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 145. Australia Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 146. Australia Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 147. Rest of Asia-Pacific Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 148. Rest of Asia-Pacific Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 149. Rest of Asia-Pacific Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 150. Europe Metabolic Disease Treatment, by Country USD Million (2025-2030)
  • Table 151. Europe Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 152. Europe Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 153. Europe Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 154. Germany Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 155. Germany Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 156. Germany Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 157. France Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 158. France Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 159. France Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 160. Italy Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 161. Italy Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 162. Italy Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 163. United Kingdom Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 164. United Kingdom Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 165. United Kingdom Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 166. Netherlands Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 167. Netherlands Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 168. Netherlands Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 169. Rest of Europe Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 170. Rest of Europe Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 171. Rest of Europe Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 172. MEA Metabolic Disease Treatment, by Country USD Million (2025-2030)
  • Table 173. MEA Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 174. MEA Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 175. MEA Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 176. Middle East Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 177. Middle East Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 178. Middle East Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 179. Africa Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 180. Africa Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 181. Africa Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 182. North America Metabolic Disease Treatment, by Country USD Million (2025-2030)
  • Table 183. North America Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 184. North America Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 185. North America Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 186. United States Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 187. United States Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 188. United States Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 189. Canada Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 190. Canada Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 191. Canada Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 192. Mexico Metabolic Disease Treatment, by Type USD Million (2025-2030)
  • Table 193. Mexico Metabolic Disease Treatment, by Application USD Million (2025-2030)
  • Table 194. Mexico Metabolic Disease Treatment, by Route of Administration USD Million (2025-2030)
  • Table 195. Research Programs/Design for This Report
  • Table 196. Key Data Information from Secondary Sources
  • Table 197. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Metabolic Disease Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Metabolic Disease Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Metabolic Disease Treatment: by Route of Administration USD Million (2018-2023)
  • Figure 7. South America Metabolic Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Metabolic Disease Treatment Share (%), by Country
  • Figure 9. Europe Metabolic Disease Treatment Share (%), by Country
  • Figure 10. MEA Metabolic Disease Treatment Share (%), by Country
  • Figure 11. North America Metabolic Disease Treatment Share (%), by Country
  • Figure 12. Global Metabolic Disease Treatment share by Players 2023 (%)
  • Figure 13. Global Metabolic Disease Treatment share by Players (Top 3) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 16. Merck & Co., Inc (United States) Revenue: by Geography 2023
  • Figure 17. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 21. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 23. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 24. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2023
  • Figure 25. Kowa Pharmaceuticals America, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 26. Kowa Pharmaceuticals America, Inc (United States) Revenue: by Geography 2023
  • Figure 27. Global Metabolic Disease Treatment: by Type USD Million (2025-2030)
  • Figure 28. Global Metabolic Disease Treatment: by Application USD Million (2025-2030)
  • Figure 29. Global Metabolic Disease Treatment: by Route of Administration USD Million (2025-2030)
  • Figure 30. South America Metabolic Disease Treatment Share (%), by Country
  • Figure 31. Asia Pacific Metabolic Disease Treatment Share (%), by Country
  • Figure 32. Europe Metabolic Disease Treatment Share (%), by Country
  • Figure 33. MEA Metabolic Disease Treatment Share (%), by Country
  • Figure 34. North America Metabolic Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc (United States)
  • Novartis International AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • AstraZeneca plc (United Kingdom)
  • C.H. Boehringer Sohn AG & Ko. KG (Germany)
  • Kowa Pharmaceuticals America, Inc (United States)
Additional players considered in the study are as follows:
LG Life Science (South Korea) , Mitsubishi Tanabe Pharma Corporation (Japan) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 208 Pages 72 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Metabolic Disease Treatment Market Quantitative research analysis
Global Metabolic Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck & Co., Inc (United States), Novartis International AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca plc (United Kingdom), C.H. Boehringer Sohn AG & Ko. KG (Germany) and Kowa Pharmaceuticals America, Inc (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in Drug Delivery Technologies" is seen as one of major influencing trends for Metabolic Disease Treatment Market during projected period 2023-2030.
The Metabolic Disease Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Metabolic Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Gynecological Cancer Drugs Comprehensive Study by Type (Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer), Application (Hospital, Clinic, Other), Physical Examination...
$ 3750
Hyperlipidemia Drugs Comprehensive Study by Drugs (Statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin), Bile-acid-Binding Resins (cholestyramine, ...
$ 3750
Recombinant Human Growth Hormone Comprehensive Study by Application (Growth Hormone (GH) Deficiency, Adult GH Deficiency, Pediatric GH Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Wi...
$ 3750
Pegfilgrastim Biosimilar Comprehensive Study by Type (Ristempa, Tezmota, Fulphila, Pelgraz, Udenyca), Application (Chemotherapy Induced Neutropenia, Transplantation, Others), Distribution Channel (Ho...
$ 3650
Lurasidone Comprehensive Study by Type (20mg/tablet, 40mg/tablet, 60mg/tablet, 80mg/tablet, 120mg/tablet), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End-user (...
$ 3350
Peptide Based Cardiovascular Therapeutics Comprehensive Study by Type (Generic, Innovative), Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others), Synthesis Technology (...
$ 3450